97 related articles for article (PubMed ID: 23651023)
1. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
[TBL] [Abstract][Full Text] [Related]
2. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
[TBL] [Abstract][Full Text] [Related]
3. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
4. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
[TBL] [Abstract][Full Text] [Related]
5. Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
André-Kerneïs E; Leroy-Matheron C; Gouault-Heilmann M
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):761-4. PubMed ID: 14614357
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
7. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
8. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
[TBL] [Abstract][Full Text] [Related]
11. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
Schalekamp T; Boink GJ; Visser LE; Stricker BH; de Boer A; Klungel OH
Clin Pharmacol Ther; 2006 Jun; 79(6):511-20. PubMed ID: 16765138
[No Abstract] [Full Text] [Related]
13. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
[TBL] [Abstract][Full Text] [Related]
14. Genetic and environmental risk factors for oral anticoagulant overdose.
Verstuyft C; Robert A; Morin S; Loriot MA; Flahault A; Beaune P; Funck-Brentano C; Jaillon P; Becquemont L
Eur J Clin Pharmacol; 2003 Mar; 58(11):739-45. PubMed ID: 12634980
[TBL] [Abstract][Full Text] [Related]
15. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.
Teichert M; van Noord C; Uitterlinden AG; Hofman A; Buhre PN; De Smet PA; Straus S; Stricker BH; Visser LE
Br J Haematol; 2011 May; 153(3):379-85. PubMed ID: 21418179
[TBL] [Abstract][Full Text] [Related]
17. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
[TBL] [Abstract][Full Text] [Related]
18. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
19. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
[TBL] [Abstract][Full Text] [Related]
20. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients.
Montes R; Nantes O; Alonso A; Zozaya JM; Hermida J
Br J Haematol; 2008 Dec; 143(5):727-33. PubMed ID: 18950464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]